NCT02737605View on ClinicalTrials.gov

A Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

February 23, 2017

Study Completion Date

February 23, 2017

Conditions
Healthy
Interventions
DRUG

Intranasal Esketamine

Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.

DRUG

Intravenous Esketamine

Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.

DRUG

Moxifloxacin

Participants will receive 400 mg Moxifloxacin orally.

DRUG

Oral Placebo

Participants will receive matching placebo orally.

DRUG

Intravenous Placebo

Participants will receive placebo 40 minutes, intravenous infusion.

DRUG

Intranasal Placebo

Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).

Trial Locations (1)

Unknown

Berlin

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02737605 - A Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Participants | Biotech Hunter | Biotech Hunter